Gland Pharma Limited (NSE:GLAND) Q4 FY23 Earnings Concall dated May. 18, 2023. Corporate Participants: Sumanta Bajpayee -- Vice President, Finance and Investor Relations Srinivas
Gland Pharma Limited (GLAND) Q4 FY23 Earnings Concall Transcript
Categories
Health Care
Divi’s Laboratories Ltd (DIVISLAB) Q4 FY23 Earnings Concall Transcript
Divi's Laboratories Ltd (NSE: DIVISLAB) Q4 FY23 Earnings Concall dated May. 20, 2023 Corporate Participants: M. Satish Choudhury -- Company Secretary and Chief Investor
Zydus Lifesciences Ltd (ZYDUSLIFE) Q4 FY23 Earnings Concall Transcript
Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) Q4 FY23 earnings concall dated May. 18, 2023 Corporate Participants: Ganesh Nayak -- Executive Director Sharvil Patel -- Managing Director Nitin
Zydus Lifescience Ltd Q4FY23 results out, revenue grows by 32%
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble
Shalby Ltd Q4FY23 results out, net profit grows by 40%
Shalby Ltd reported Total revenue for Q4 FY23 of ₹199 Crore, up from ₹163 Crore year on year depicting a growth of
Shalby Ltd Q4FY23 results out, revenue grows by 22%
Shalby Ltd is engaged in healthcare delivery space in India. It operates a chain of multi-specialty hospitals across India. The business of
Metropolis Healthcare Limited (METROPOLIS) Q4 FY23 Earnings Concall Transcript
Metropolis Healthcare Limited (NSE: METROPOLIS) Q4 FY23 earnings concall dated May. 16, 2023 Corporate Participants: Ameera Shah -- Managing Director Surendran Chemmenkotil -- Chief Executive Officer
Zydus Wellness Ltd (ZYDUSWELL) Q4 FY23 Earnings Concall Transcript
Zydus Wellness Ltd (NSE: ZYDUSWELL) Q4 FY23 earnings concall dated May. 17, 2023 Corporate Participants: Tarun Arora -- Chief Executive Officer and Whole Time
Max Healthcare Institute Ltd (MAXHEALTH) Q4 FY23 Earnings Concall Transcript
Max Healthcare Institute Ltd (NSE: MAXHEALTH) Q4 FY23 earnings concall dated May. 17, 2023 Corporate Participants: Abhay Soi -- Chairman and Managing Director Yogesh
Procter & Gamble Health Q4FY23 Earnings
P&G Health Ltd. manufactures and sells medications and chemicals. Financial Results: Procter & Gamble Health Limited reported Total Income for Q4FY23 of
Granules India Ltd (GRANULES) Q4 FY23 Earnings Concall Transcript
Granules India Ltd (NSE:GRANULES) Q4 FY23 Earnings Concall dated May. 16, 2023. Corporate Participants: Irfan Raeen -- Investor Relations Krishna Prasad -- Chairman and Managing Director
Max Healthcare Inst 4Q23; 85% Growth in Profit
Max Healthcare Institute’s revenue in Q4FY23 rose 26% to ₹ 1,637 crores. Consolidated Profit After Tax came at ₹ 320 crores in
Pfizer Limited Q4FY23 Earnings Story
Pharmaceutical product manufacture, marketing, trade, and export are all activities of Pfizer Ltd. It produces goods in-house and also works with several
Themis Medicare Ltd (THEMISMED) Q4 FY23 Earnings Concall Transcript
Themis Medicare Ltd (NSE: THEMISMED) Q4 FY23 earnings concall dated May. 15, 2023 Corporate Participants: Sachin Patel -- Managing Director and Chief Executive Officer
Rainbow Children’s Medicare Ltd (RAINBOW) Q4 FY23 Earnings Concall Transcript
Rainbow Children's Medicare Ltd (NSE: RAINBOW) Q4 FY23 earnings concall dated May. 15, 2023 Corporate Participants: Ramesh Kancharla -- Chairman and Managing Director Sanjeev
Gujarat Themis Biosyn Limited (506879) Q4 FY23 Earnings Concall Transcript
Gujarat Themis Biosyn Limited (NSE: 506879) Q4 FY23 earnings concall dated May. 15, 2023 Corporate Participants: Sachin Dinesh Patel -- Director Rajneesh Anand -- Consultant Tushar
Rainbow Children’s Medicare Q4FY23 Earnings
An Indian hospital network with many specialties in paediatrics, obstetrics, and gynaecology is run by Rainbow Children's Medicare Limited. The business provides
Cipla Limited Q4 FY23 Earnings Conference Call Insights
Key highlights from Cipla Limited (CIPLA) Q4 FY23 Earnings Concall Management Update: [00:05:08] CIPLA said its U.S. business crossed $200 million in
Cipla Limited (CIPLA) Q4 FY23 Earnings Concall Transcript
Cipla Limited (NSE:CIPLA) Q4 FY23 Earnings Concall dated May. 12, 2023. Corporate Participants: Ajinkya Pandharkar -- Investor Relations Umang Vohra -- Managing Director and Global Chief
Solara Active Pharma Sciences Limited (SOLARA) Q4 FY23 Earnings Concall Transcript
Solara Active Pharma Sciences Limited (NSE:SOLARA) Q4 FY23 Earnings Concall dated May. 12, 2023. Corporate Participants: Abhishek Singhal -- Investor Relations Jitesh Devendra -- Managing Director
Dr Lal PathLabs Ltd Q4 FY23 Earnings Conference Call Insights
Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q4 FY23 Earnings Concall Q&A Highlights: [00:17:48] Rahul Agarwal from InCred Capital asked if